These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16951028)

  • 41. A comparison of antibiotic use in children between Canada and Denmark.
    Marra F; Monnet DL; Patrick DM; Chong M; Brandt CT; Winters M; Kaltoft MS; Tyrrell GJ; Lovgren M; Bowie WR
    Ann Pharmacother; 2007 Apr; 41(4):659-66. PubMed ID: 17374628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population.
    Hall MM; Finnoff JT; Smith J
    PM R; 2011 Feb; 3(2):132-42. PubMed ID: 21333952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections.
    Betrosian AP; Douzinas EE
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1099-112. PubMed ID: 19621991
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of cranial fixation pins in pediatric neurosurgery.
    Berry C; Sandberg DI; Hoh DJ; Krieger MD; McComb JG
    Neurosurgery; 2008 Apr; 62(4):913-8; discussion 918-9. PubMed ID: 18496197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic fluoroquinolone prescriptions for hospitalized children in Belgium, results of a multicenter retrospective drug utilization study.
    Meesters K; Mauel R; Dhont E; Walle JV; De Bruyne P
    BMC Infect Dis; 2018 Feb; 18(1):89. PubMed ID: 29471791
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fluoroquinolones in paediatrics--1995.
    Dagan R
    Drugs; 1995; 49 Suppl 2():92-9. PubMed ID: 8549423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
    Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of fluoroquinolones in children: recent advances.
    Velissariou IM
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):853-60. PubMed ID: 17140360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluoroquinolones in children: update of the literature.
    Bacci C; Galli L; de Martino M; Chiappini E
    J Chemother; 2015 Oct; 27(5):257-65. PubMed ID: 26099190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Adverse effects and interactions of fluoroquinolones].
    Sepcić K; Perković O; Turel I; Sepcić J
    Lijec Vjesn; 2009; 131(3-4):74-80. PubMed ID: 19514253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse.
    Wong-Beringer A; Nguyen LH; Lee M; Shriner KA; Pallares J
    Pharmacotherapy; 2009 Jun; 29(6):736-43. PubMed ID: 19476424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Escherichia coli from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams.
    Kariuki S; Revathi G; Corkill J; Kiiru J; Mwituria J; Mirza N; Hart CA
    J Infect Dev Ctries; 2007 Dec; 1(3):257-62. PubMed ID: 19734602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibiotic usage, dosage and course length in children between 0 and 4 years.
    de Jong J; van den Berg PB; Visser ST; de Vries TW; de Jong-van den Berg LT
    Acta Paediatr; 2009 Jul; 98(7):1142-8. PubMed ID: 19397542
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical inquiries. Is there much risk in using fluoroquinolones in children?
    Hernandez R; Edgerton L; Flake D; Groetsch SM
    J Fam Pract; 2008 Aug; 57(8):539-40. PubMed ID: 18687231
    [No Abstract]   [Full Text] [Related]  

  • 59. Weighing the adverse cardiac effects of fluoroquinolones: A risk perspective.
    Mehrzad R; Barza M
    J Clin Pharmacol; 2015 Nov; 55(11):1198-206. PubMed ID: 26011799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.
    Wang JG; Cui HR; Hu YS; Tang HB
    Medicine (Baltimore); 2020 Aug; 99(34):e21860. PubMed ID: 32846837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.